Skip to Main Content
Center for Cancer ResearchCCR Home | About CCR | CCR Intranet

Headline Title

Pharmacology and Experimental Therapeutics Section and Genetic Tumor Predisposition Program: Staff

Brigitte Widemann, M.D., Section Head

A photo of Brigitte Widemann, M.D., Section Head
Brigitte Widemann, M.D., Section Head

Dr. Widemann is the head of the PET section. She obtained her MD from the University of Cologne, Cologne Germany, where she also completed her pediatric residency. She moved to the Unites States to train as a fellow for pediatric hematology and oncology at the NCI, Pediatric Branch in 1992. She joined the Pharmacology and Experimental Therapeutics Section under the leadership of Dr. Frank Balis for her research, and has since remained with the PET Section. Dr. Widemann and her colleagues developed novel imaging methods for NF1 related plexiform neurofibromas and pioneered the development of early phase drug treatments for this patient population. Dr.Widemann leads multiple clinical trials of new investigational agents in pediatric refractory cancers and NF1. Dr. Widemann serves as the NCI Pediatric Oncology Branch Principal Investigator of the Children’s Oncology Group Phase I Consortium and of the Department of Defense sponsored Neurofibromatosis Consortium. She became Section Head of the PET Section in 2009. Her research interests are in the development of early clinical trials for children and young adults with refractory cancers and genetic tumor predisposition syndromes such as NF1 and MEN2A and MEN2B.

Dashed Line

return to the top

This Page Last Reviewed on February 26, 2013

About CCR | Clinical Trials | Research | Employment | Initiatives | News | Events | Site Privacy Policy | Accessibility

A Service of the National Cancer Institute

Department of Health and Human Services National Institutes of Health (NIH) USA Gov